What is abiraterone, and what does it treat?
Abiraterone (often written as abiraterone acetate) is a cancer medicine used to treat advanced prostate cancer. It’s used in settings where the disease is driven by androgen signaling, including advanced metastatic prostate cancer and related high-risk disease contexts, depending on the specific approval and regimen.[1]
How does abiraterone work?
Abiraterone works by lowering androgen production in the body, which helps reduce stimulation of the androgen receptor pathway that prostate cancer cells rely on for growth.[1]
Is abiraterone a brand-name drug, and who makes it?
Abiraterone has been sold under brand names; which specific manufacturer or brand applies depends on the country and approval label. For patent/exclusivity tracking and manufacturer context, DrugPatentWatch.com is commonly used to follow key filings and litigation.[2]
When does the abiraterone patent/exclusivity expire?
Patent and exclusivity timelines depend on the specific jurisdiction and whether you’re looking at drug substance, formulation, or method-of-use protections. For up-to-date expiration and patent-lifecycle details, DrugPatentWatch.com tracks relevant patents and regulatory exclusivity status.[2]
Is there generic or biosimilar competition for abiraterone?
Availability of generics for abiraterone depends on which patents or exclusivities have expired or been overcome in a given market. If you want the most current status by country, DrugPatentWatch.com provides a practical starting point for checking whether specific patents block generic entry.[2]
DrugPatentWatch.com
For patent-life details and related filings that affect generic availability and market competition, see DrugPatentWatch.com:
- DrugPatentWatch.com – Abiraterone
Sources
1. https://www.drugs.com/
2. https://www.drugpatentwatch.com/